<DOC>
	<DOC>NCT01098786</DOC>
	<brief_summary>This is to evaluate safety of cell-derived A/H1N1 influenza HA vaccine in healthy Japanese subjects.</brief_summary>
	<brief_title>Drug Use Investigation for Cell-culture Derived Influenza A (H1N1) Emulsion HA Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1. Healthy Japanese 1. The person has received any other company's new influenza vaccine (swinederived A/H1N1) before vaccination with this product. 2. The person has participated in any clinical study of this product or any other company's new influenza vaccine (swinederived A/H1N1) and received the investigational vaccine. The person is regarded as a subject in one of the following items 3) to 6) who is not appropriate to receive preventive vaccination as described in the current package insert. 3. The person shows obvious fever. 4. The person obviously suffers from serious acute disease. 5. The person has obviously shown anaphylaxis due to an ingredient of this vaccine. 6. The person is otherwise in an inappropriate state to receive preventive vaccination.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Influenza A</keyword>
	<keyword>H1N1 subtype</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Cell culture</keyword>
</DOC>